CoChat

Vancomycin Heteroresistance and Methicillin-Resistant Staphylococcus aureus

Deresinski, Stan · 2009 · Journal of Infectious Diseases
Cited by 55

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Heteroresistance refers to the presence, within a larger population of fully antimicrobial-susceptible microorganisms, of subpopulations with lesser susceptibility. This phenomenon has been described in a wide range of microorganisms, but much recent attention has been directed toward its expression in Staphylococcus aureus . Although it has long been known that resistance to methicillin is characteristically heterogeneously expressed by this organism [ 1 ], the current focus revolves around its heteroresistance to vancomycin. Heteroresistant subpopulations of vancomycin-susceptible S. aureus (hVISA) were first described in 1997 [ 2 ], shortly after the initial description of vancomycin intermediately susceptible strains (VISA) [ 3 ]. hVISA have minimum inhibitory concentrations (MICs) in the intermediately susceptible range and likely represent a step on the path to the development of a fully VISA population hVISA have been identified among clinical isolates of MRSA at widely varying frequencies, but some recent US reports have been more consistent. During 2003–2007, the proportion of MRSA found to harbor hVISA by the macro Etest in 3 Detroit-area hospitals was 8.3%; this represented an increase from 2.2% in 1986–1993 and occurred without a contemporaneous increase in VISA isolations [ 4 ]. This prevalence in the most recent period is similar to that found in a prospective trial of treatment of S. aureus bacteremia and endocarditis (mostly in the United States), in which 7 (8%) of 89 MRSA isolates, were vancomycin heteroresistant [ 5 ]. Vancomycin heteroresistance is present in both hospital and community strains of S. aureus; in the Detroit experience, 56.9% of hVISA belonged to SCC mec type II and 39.4% to SCC mec type IV [ 4 ]. The proportion of methicillin-resistant S. aureus (MRSA) isolates demonstrating heteroresistance increases with increasing vancomycin MICs, but heteroresistance is observed in strains with MICs as low as 1.0 μg/mL [ 6 ]. The phenomenon is inducible and may be either stable or unstable [ 7 ] hVISA are not detected by standard susceptibility testing methods because they are ordinarily present at frequencies of only 10 −5 to 10 −6 [ 6 ]. The gold standard for the identification of hVISA is population analysis, but this is a labor-intensive process not suitable for the clinical microbiology laboratory. An alternative method, the macro Etest, has recently been reported to have, relative to population analysis, sensitivities of 80% and 94% and specificities of 87% and 96% for detection of hVISA/VISA when examined at 24 h and 48 h, respectively [ 8 ]. The macro Etest, however, requires use of a nonstandard medium and inoculum. A newer method, the Etest GRD strip with incorporation of a nutrient that enhances growth of hVISA/VISA, uses a standard inoculum and medium and has sensitivities of 74% and 94% and specificities of 100% and 95% when read at 24 h and 48 h, respectively [ 8 ] hVISA and VISA generally have a characteristic phenotype, with a thickened cell wall and increased d -ala- d -ala moieties, together with abnormal muropeptide residues and diminished cross-linking of peptidoglycan in association with reduced autolytic activity and slow growth in vitro [ 9 , 10 ]. The excess dipeptides are believed to “trap” vancomycin, and this, together with the thickened cell wall, may act as a barrier to the diffusion of this large (molecular weight, 1485.7) glycopeptide molecule [ 11 , 12 ]. It has been speculated that the thickened cell wall may also act as a barrier to daptomycin (molecular weight, 1620.7), thus accounting for vancomycin induction of daptomycin heteroresistance and a reported parallel increase in MIC for this lipopeptide in some isolates [ 13 , 14 ]. The development of this phenotype, which can be demonstrated on in vitro passage in the presence of vancomycin, has previously been associated with overexpression of genes of the cell wall stimulon [ 15 ], a group of genes induced by stress, such as exposure to cell wall–active antibiotics [ 16 ]. Mutations resulting in upregulation of one of these operons, VraSR (vancomycin resistance–associated sensor/regulator), which encodes a 2-component histidine kinase response regulator, have been associated with the emergence of VISA in some but not all isolates [ 17–19 ]. Mutation of graS the sensor component of another putative 2-component system, has alternatively been implicated, but full expression of reduced vancomycin susceptibility apparently requires >1 locus mutation [ 18 , 20 ]. In contrast to these findings, however, transcriptome analysis of a set of strains found no evidence of upregulation of vraSR or the cell wall stimulon but did identify multiple varying mutations, even among isolates of the same multilocus sequence type [ 19 ]. This suggests that, instead of single initial signature mutation, there may be multiple potential transcriptional pathways leading to the development of reduced vancomycin susceptibility [

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1086/596630

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 55

Metadata

Authors
Deresinski, S.
Venue
Journal of Infectious Diseases
Published
2009-03-01
Volume
199
Issue
5
Pages
605-609
ISSN
  • 0022-1899 (ISSN-L)
  • 1537-6613
OpenAlex
W2008192713
Cited by
55
References
3
FWCI
5.03
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vancomycin Heteroresistance and Methicillin-Resistant Staphylococcus aureus. https://app.cochat.ai/papers/10.1086/596630
The paper
Deresinski, S. (2009). Vancomycin Heteroresistance and Methicillin-Resistant Staphylococcus aureus. Journal of Infectious Diseases. https://doi.org/10.1086/596630

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.